SEHK:2171Biotechs
Will Dispatch Bio CAR T Solid Tumor Trial Shift CARsgen Therapeutics' (SEHK:2171) Narrative?
In January 2026, Dispatch Bio and CARsgen Therapeutics announced a clinical collaboration in China to start a Phase 1 trial evaluating DISP-11, which combines Dispatch’s Flare platform and DV-10 virus with CARsgen’s approved BCMA-targeting CAR T therapy zevor-cel in patients with epithelial solid tumors.
This alliance is significant because it seeks to adapt a multiple myeloma CAR T-cell therapy for solid tumors, an area where immunotherapies have historically faced major biological...